Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study

Swerdlow, Anthony; Higgins, Craig; Smith, Paul J.; Cunningham, David; Hancock, Barry W.; Horwich, A.; Hoskin, Peter; Lister, T. Andrew; Radford, John; Rohatiner, A. Z. S.; Linch, David C.

doi:10.1200/jco.2011.34.8268

Cited by 184 publications

(162 citation statements)

References 49 publications

(20 reference statements)

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…Both radiotherapy and alkylating chemotherapy contribute to the risk of lung cancer after HL. 5 The risk of lung cancer is directly related to radiation dose, as shown in a case-control study in which patients who received a dose of 30 Gy or higher had a 7-to 9-fold higher lung cancer risk compared with those who received ,5 Gy to the area of the lung in which the cancer developed (P , .001 for trend). 19 Similarly, a significant correlation between number of cycles of alkylating chemotherapy for HL and lung cancer risk has also been demonstrated.…”

Section: Second Malignancymentioning

confidence: 99%

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

2014

Blood

View full text Add to dashboard Cite

Long-term survivors of Hodgkin lymphoma (HL) are at an increased risk for a range of late complications, with subsequent malignant neoplasm and cardiovascular disease representing the 2 leading causes of death in these patients. Raising awareness, close follow-up, and adoption of selected earlydetection and risk-reduction strategies may help to reduce the adverse impact of these late effects on patients. This chapter reviews known long-term complications of HL therapy, risk factors, and the timing of their occurrence. Where available, data on the efficacy of screening for selected late effects of HL are presented. Current evidence-based and consensus-based recommendations on follow-up of longterm HL survivors are also reviewed. As HL therapy evolves over time, late effects and implications on follow-up of patients treated in the contemporary era should be considered and opportunities for future research should be explored. (Blood. 2014; 124(23):3373-3379)

show abstract

Section: Second Malignancymentioning

confidence: 99%

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

2014

Blood

View full text Add to dashboard Cite

show abstract

“…Treatment-related factors are presumed to be responsible for the elevated risk of myelodysplastic syndrome, lung cancer, nonHodgkin's lymphoma and acute myeloid leukemia in patients treated with chemotherapy for distinct primary malignancies, such as hematologic and non-hematologic malignancies and Hodgkin's lymphoma (Swerdlow et al 2011, Godley and Larson 2008, Leone et al 2007). These studies show that there is a need for careful long-term monitoring of patients receiving chemotherapy for a primary condition, for the early detection and treatment of secondary cancers (Freeman et al 2012, Papanikolaou et al 2011, Swerdlow et al 2011, Yamada et al 1999 …”

Section: Discussionmentioning

confidence: 99%

Gene homozygosis and mitotic recombination induced by camptothecin and irinotecan in Aspergillus nidulans diploid cells

Esquissato

Sant’Anna

Franco

et al. 2014

An. Acad. Bras. Ciênc.

View full text Add to dashboard Cite

Mitotic recombination is a process involved in carcinogenesis which can lead to genetic loss through the loss of heterozygosity. The recombinogenic potentials of two anticancer drugs topoisomerase I inhibitors, camptothecin (CPT) and irinotecan (CPT-11), were evaluated in the present study. The homozygotization assay, which assess the induction of mitotic recombination and gene homozygosis, as well as the heterozygous A757//UT448 diploid strain of Aspergillus nidulans were employed. The three non-cytotoxic concentrations of CPT (3.5 ng mL -1 , 10.5 ng mL -1 and 17.4 ng mL -1 ) were found to induce both mitotic recombination and gene homozygosis. CPT treatment produced three diploids homozygous, for nutritional and conidia color genes, and Homozygotization Indices (HI) significantly different from negative control. On the other hand, only the highest CPT-11 concentration tested (18 µg mL -1 ), corresponding to the maximal single chemotherapeutic dose, produced HI values higher than 2.0 and significantly different from negative control HI values. The recombinogenic effects of both topoisomerase I blockers were associated with the recombinational repair of DNA strand breaks induced by CPT and CPT-11. The anticancer drugs CPT and CPT-11 may be characterized as secondary malignancies promoters in cancer patients after chemotherapy treatment.

show abstract

“…Общими тенденциями тера-пии являются адаптация объема терапии к риску про-грессии, отказ или снижение объема лучевой терапии, использование препаратов, обладающих минималь-ным канцерогенным потенциалом, сохранение фер-тильности [9][10][11][12][13][14]. Наше исследование показывает, что применение этих принципов на практике нуждается в совершенствовании.…”

Section: вторая опухольunclassified

Treatment patterns, outcomes and long-term toxicity among patients with Hodgkin’s lymphoma in real world: results of a hospital based registry

Никитин¹,

Н²,

Маркарян³

et al. 2016

Onkogematologiâ

View full text Add to dashboard Cite

Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study

Cited by 184 publications

References 49 publications

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Gene homozygosis and mitotic recombination induced by camptothecin and irinotecan in Aspergillus nidulans diploid cells

Treatment patterns, outcomes and long-term toxicity among patients with Hodgkin’s lymphoma in real world: results of a hospital based registry

Contact Info

Product

Resources

About